Helio Genomics and LiverRight have entered into a partnership designed to improve access to early liver cancer detection in the US.

As the diagnostic landscape evolves, several patterns are emerging across both clinical research and market innovation.

Artificial intelligence is no longer just spotting tumors a little faster than humans. In study after study, machine learning systems are uncovering hidden patterns in cancer data that even veteran ...

OncoInv, a Netherlands-based company focused on multi-cancer early detection, has signed a distribution agreement with MaxBloch Clinical Laboratories to introduce OncoSeek(R) , its multi-cancer early ...

The blood-based test by Astrin Biosciences shows high sensitivity and specificity across cancer stages and subtypes, ...

Cancer remains a leading cause of morbidity and mortality worldwide, presenting immense challenges to public health systems. Despite major advances in ...

Researchers have developed an AI-based tool that accelerates the detection of kidney cancer. Its effectiveness was validated ...

Expanding U.S. market access with an experienced technology investor and AI-driven growth strategistVancouver, British Columbia--(Newsfile Corp. - December 30, 2025) - BioMark Diagnostics Inc. (CSE: ...

Company engages Standards Council of Canada; targets ISO 15189 accreditation for early 2026Vancouver, British Columbia--(Newsfile Corp. - December 23, 2025) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: ...